Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;21(1):44-52.
doi: 10.7861/clinmed.2020-0980.

Management of functional gastrointestinal disorders

Affiliations

Management of functional gastrointestinal disorders

Asma Fikree et al. Clin Med (Lond). 2021 Jan.

Abstract

Functional gastrointestinal (GI) disorders (eg irritable bowel syndrome and functional dyspepsia) are very common conditions which are associated with very poor quality of life and high healthcare utilisation. They are caused by disorders of GI functioning, namely altered gut sensitivity, motility, microbiota, immune functioning and central nervous system processing. They cause chronic symptoms throughout the gut (eg pain, dyspepsia and altered bowel habit), all of which are made worse by maladaptive patient behaviours, stress and psychological comorbidity. Management involves a biopsychosocial approach involving changes in lifestyle and diet, addressing coexisting psychological comorbidity and using medication to treat underlying pathophysiology. Pharmacological treatment with antispasmodics, neuromodulators, motility agents and antidepressants is effective. Psychotherapy in motivated individuals is equally effective. Success of treatment is increased by a good doctor-patient relationship and so this needs to be taken into account during the consultation.

Keywords: functional disorders; functional dyspepsia; gastrointestinal; irritable bowel syndrome; pain.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Biopsychosocial model of functional gastrointestinal disorders. CNS = central nervous system; ENS = enteric nervous system; FGID = functional gastrointestinal disorders.
Fig 2.
Fig 2.
Algorithms for pharmacological management of irritable bowel syndrome and functional dyspepsia. a) Irritable bowel syndrome. Dotted red boxes identify medications that are useful for more than one symptom in IBS-D, dotted blue boxes identify medications that are useful for combination symptoms in IBS-C. b) Functional dyspepsia. Dotted blue boxes identify medicines that target for both nutrient tolerance and pain. PPI = proton pump inhibitor; SNRI = serotonin noradrenergic reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.

References

    1. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016;150:1262– 79.e2. - PubMed
    1. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology 2020. [Epub ahead of print]. - PubMed
    1. Jones MP, Crowell MD, Olden KW, Creed F. Functional gastrointestinal disorders: an update for the psychiatrist. Psychosomatics 2007;48:93–102. - PubMed
    1. Shivaji UN, Ford AC. Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic. Frontline Gastroenterol 2014;5:266–71. - PMC - PubMed
    1. Aziz I, Palsson OS, Tornblom H, et al. The prevalence and impact of overlapping rome iv-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization: a cross-sectional general population study in three countries. Am J Gastroenterol 2018;113:86–96. - PubMed

MeSH terms